Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P2-VP8 subunit vaccine
- Development stage
- Unknown
- Lead developer
- PATH
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The P2-VP8 subunit vaccine is a non-replicating, recombinant protein subunit vaccine developed by PATH for the prevention of rotavirus gastroenteritis. Unlike traditional oral live-attenuated rotavirus vaccines, this candidate is administered parenterally via intramuscular injection, which may improve efficacy in low-income settings where oral vaccines often underperform. The vaccine is composed of a truncated VP8 subunit protein derived from the rotavirus outer capsid spike protein VP4, fused to a universal T-cell epitope (P2) from tetanus toxin to enhance the immune response. It is expressed in Escherichia coli and formulated with an aluminum hydroxide adjuvant (Alhydrogel). The vaccine has been developed in both monovalent (targeting the P[8] genotype) and trivalent (targeting P[4], P[6], and P[8] genotypes) formulations, and clinical trials have demonstrated its safety and immunogenicity in infants and toddlers.
- Other names
- P2-VP8 subunit parenteral rotavirus vaccineP-2-VP8 subunit parenteral rotavirus vaccineP 2-VP8 subunit parenteral rotavirus vaccineP2-VP8-P[8] monovalent vaccineP2-VP8-P[4],[6],[8] trivalent vaccine
02
Targets
VP4 (Rotavirus VP4)
Beyond the preview
Go deeper on P2-VP8 subunit vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on P2-VP8 subunit vaccine.